Amgen Inc. (NASDAQ:AMGN) Shares Sold by Putnam Investments LLC

Posted by Defense World Staff on Jun 13th, 2023

Putnam Investments LLC cut its position in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 1.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 676,258 shares of the medical research company’s stock after selling 10,191 shares during the quarter. Putnam Investments LLC owned about 0.13% of Amgen worth $177,612,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cooper Financial Group grew its stake in shares of Amgen by 0.5% in the fourth quarter. Cooper Financial Group now owns 7,807 shares of the medical research company’s stock worth $2,050,000 after purchasing an additional 37 shares during the last quarter. Obermeyer Wood Investment Counsel Lllp grew its stake in shares of Amgen by 1.3% in the third quarter. Obermeyer Wood Investment Counsel Lllp now owns 2,959 shares of the medical research company’s stock worth $667,000 after purchasing an additional 38 shares during the last quarter. Howard Financial Services LTD. boosted its position in Amgen by 2.4% during the fourth quarter. Howard Financial Services LTD. now owns 1,647 shares of the medical research company’s stock valued at $433,000 after acquiring an additional 39 shares during the last quarter. Calamos Wealth Management LLC boosted its position in Amgen by 2.2% during the fourth quarter. Calamos Wealth Management LLC now owns 1,822 shares of the medical research company’s stock valued at $479,000 after acquiring an additional 39 shares during the last quarter. Finally, Stonebridge Capital Advisors LLC boosted its position in Amgen by 5.2% during the third quarter. Stonebridge Capital Advisors LLC now owns 814 shares of the medical research company’s stock valued at $183,000 after acquiring an additional 40 shares during the last quarter. 75.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Piper Sandler cut their price target on shares of Amgen from $293.00 to $288.00 in a research report on Friday, April 28th. Wells Fargo & Company raised shares of Amgen from an “equal weight” rating to an “overweight” rating and cut their price target for the company from $275.00 to $265.00 in a research report on Monday, March 13th. Truist Financial cut their price objective on shares of Amgen from $280.00 to $260.00 and set a “buy” rating on the stock in a research report on Monday, February 13th. Oppenheimer cut their price objective on shares of Amgen from $292.00 to $290.00 and set an “outperform” rating on the stock in a research report on Monday, April 24th. Finally, StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 8th. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Amgen has an average rating of “Hold” and a consensus target price of $250.94.

Amgen Trading Down 0.6 %

NASDAQ:AMGN opened at $217.36 on Tuesday. The company has a debt-to-equity ratio of 11.36, a quick ratio of 2.79 and a current ratio of 3.14. The firm has a market cap of $116.14 billion, a price-to-earnings ratio of 14.78, a price-to-earnings-growth ratio of 1.72 and a beta of 0.64. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $296.67. The firm has a 50-day moving average price of $233.71 and a two-hundred day moving average price of $246.78.

Amgen (NASDAQ:AMGN – Get Rating) last posted its quarterly earnings data on Thursday, April 27th. The medical research company reported $3.98 EPS for the quarter, beating the consensus estimate of $3.84 by $0.14. The firm had revenue of $6.11 billion during the quarter, compared to analyst estimates of $6.18 billion. Amgen had a net margin of 30.23% and a return on equity of 248.47%. The company’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same quarter last year, the business posted $4.25 EPS. On average, equities analysts expect that Amgen Inc. will post 18.12 earnings per share for the current fiscal year.

Amgen Profile

(Get Rating)

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen Inc. (NASDAQ:AMGN) Shares Sold by Putnam Investments LLC

Analyst Upgrades and Downgrades

Amgen Trading Down 0.6 %

Amgen Profile

Further Reading

You might be interested in: